2019
Renal Effects of Intensive Volume Removal in Heart Failure Patients With Preexisting Worsening Renal Function
Rao VS, Ahmad T, Brisco-Bacik MA, Bonventre JV, Wilson FP, Siew ED, Felker GM, Anstrom KK, Mahoney DD, Bart BA, Tang WHW, Velazquez EJ, Testani JM. Renal Effects of Intensive Volume Removal in Heart Failure Patients With Preexisting Worsening Renal Function. Circulation Heart Failure 2019, 12: e005552. PMID: 31163974, PMCID: PMC6585463, DOI: 10.1161/circheartfailure.118.005552.Peer-Reviewed Original ResearchConceptsRenal tubular injury biomarkersTubular injury biomarkersHeart failure patientsAcute decompensated heart failure patientsDecompensated heart failure patientsTubular injury markersInjury biomarkersFailure patientsRenal functionInjury markersAcute decompensated heart failureVolume removalCARRESS-HF trialRenal function recoveryDecompensated heart failureRenal tubular injuryRenal effectsSerum creatinineTubular injuryBiomarker substudyHeart failurePharmacological therapyClinical outcomesFunction recoveryHigh incidence
2018
A meta‐analysis of MitraClip combined with medical therapy vs. medical therapy alone for treatment of mitral regurgitation in heart failure patients
Giannini C, D'ascenzo F, Fiorelli F, Spontoni P, Swaans MJ, Velazquez EJ, Armeni P, Adamo M, De Carlo M, Petronio AS. A meta‐analysis of MitraClip combined with medical therapy vs. medical therapy alone for treatment of mitral regurgitation in heart failure patients. ESC Heart Failure 2018, 5: 1150-1158. PMID: 30191666, PMCID: PMC6300824, DOI: 10.1002/ehf2.12339.Peer-Reviewed Original ResearchConceptsFunctional mitral regurgitationMedical therapyMitral regurgitationSurvival benefitConservative treatmentPercutaneous mitral valve repairEffect of MitraClipRobust survival benefitSignificant survival benefitCardiac resynchronization therapyEligible observational studiesHeart failure patientsVentricular ejection fractionMitral valve repairPatient-level analysisComprehensive literature searchStudy-level analysisConservative therapyIschemic etiologyPrimary endpointFailure patientsMultivariate adjustmentEjection fractionResynchronization therapySurvival outcomesThe Renal Effects of Aggressive Volume Removal in Heart Failure Patients with Preexisting Worsening Renal Function
Mahoney D, Ahmad T, Rao V, Brisco-Bacik M, Wilson F, Siew E, Felker G, Anstrom K, Bart B, Tang W, O'Connor C, Velazquez E, Testani J. The Renal Effects of Aggressive Volume Removal in Heart Failure Patients with Preexisting Worsening Renal Function. Journal Of Cardiac Failure 2018, 24: s26. DOI: 10.1016/j.cardfail.2018.07.074.Peer-Reviewed Original ResearchRenal tubular injury biomarkersTubular injury biomarkersRenal tubular injuryHeart failure patientsInjury biomarkersTubular injuryFailure patientsRenal functionAcute decompensated heart failure patientsDecompensated heart failure patientsVolume removalCARRESS-HF trialRenal function recoveryTubular injury markersWorsening Renal FunctionHalf of patientsADHF patientsEffective decongestionRenal effectsInjury markersPharmacologic therapyTransient findingFunction recoveryHigh incidencePatients
2017
Race and Sex Differences in QRS Interval and Associated Outcome Among Patients with Left Ventricular Systolic Dysfunction
Randolph TC, Broderick S, Shaw LK, Chiswell K, Mentz RJ, Kutyifa V, Velazquez EJ, Gilliam FR, Thomas KL. Race and Sex Differences in QRS Interval and Associated Outcome Among Patients with Left Ventricular Systolic Dysfunction. Journal Of The American Heart Association 2017, 6: e004381. PMID: 28320746, PMCID: PMC5523998, DOI: 10.1161/jaha.116.004381.Peer-Reviewed Original ResearchConceptsQRS durationBundle branch blockWhite patientsHeart failureBlack patientsBranch blockNon-left bundle branch block morphologyLeft ventricular systolic dysfunctionMultivariable Cox regression modelsBundle branch block morphologyLeft bundle branch blockMedian QRS durationVentricular systolic dysfunctionHeart failure patientsVentricular ejection fractionShorter QRS durationCox regression modelRisk of mortalityDuke University HospitalBlack individualsSex differencesCause mortalitySystolic dysfunctionCoronary angiographyEjection fraction
2016
Markers of Atherosclerosis, Clinical Characteristics, and Treatment Patterns in Heart Failure A Case-Control Study of Middle-Aged Adult Heart Failure Patients in Rural Kenya
Bloomfield GS, DeLong AK, Akwanalo CO, Hogan JW, Carter EJ, Aswa DF, Binanay C, Koech M, Kimaiyo S, Velazquez EJ. Markers of Atherosclerosis, Clinical Characteristics, and Treatment Patterns in Heart Failure A Case-Control Study of Middle-Aged Adult Heart Failure Patients in Rural Kenya. Global Heart 2016, 11: 97-107. PMID: 27102027, PMCID: PMC4843836, DOI: 10.1016/j.gheart.2015.12.014.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnkle Brachial IndexAtherosclerosisBiomarkersCardiomyopathy, DilatedCase-Control StudiesDyslipidemiasEchocardiographyElectrocardiographyFemaleGuideline AdherenceHeart FailureHumansHypertensionKenyaLogistic ModelsMaleMiddle AgedMyocardial IschemiaOdds RatioPractice Guidelines as TopicRisk FactorsRural PopulationConceptsAnkle-brachial indexAtherosclerotic risk factorsIschemic heart failureHeart failureCase-control studyWall motion abnormalitiesRisk factorsMotion abnormalitiesAdult heart failure patientsHuman immunodeficiency virus (HIV) infectionA Case-Control StudyContribution of atherosclerosisImmunodeficiency virus infectionMarker of atherosclerosisHeart failure patientsMultivariable logistic regressionPhysical examination findingsConfidence intervalsRural KenyaIschemic patternLipid testingClinical characteristicsFailure patientsMost patientsExamination findings
2015
Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial
Mentz RJ, Velazquez EJ, Metra M, McKendry C, Chiswell K, Fiuzat M, Givertz MM, Voors AA, Teerlink JR, O'Connor CM. Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. Future Cardiology 2015, 11: 585-595. PMID: 26403536, PMCID: PMC5558519, DOI: 10.2217/fca.15.56.Peer-Reviewed Original ResearchConceptsPROTECT trialComparative effectivenessHigher blood urea nitrogenEffects of torsemideProspective randomized trialsHeart failure patientsBlood urea nitrogenGreater disease severityDays postdischargeFailure patientsHeart failureLoop diureticsRandomized trialsRenal hospitalizationUrea nitrogenDisease severityPatientsFurosemideInverse probabilityTorsemideTrialsDeathOutcomesHospitalizationDiureticsTorsemide Versus Furosemide in Heart Failure Patients
Mentz RJ, Buggey J, Fiuzat M, Ersbøll MK, Schulte PJ, DeVore AD, Eisenstein EL, Anstrom KJ, O'Connor C, Velazquez EJ. Torsemide Versus Furosemide in Heart Failure Patients. Journal Of Cardiovascular Pharmacology 2015, 65: 438-443. PMID: 25945862, PMCID: PMC4423558, DOI: 10.1097/fjc.0000000000000212.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAgedComorbidityDatabases, FactualFemaleFurosemideHeart FailureHumansKaplan-Meier EstimateMaleMiddle AgedNorth CarolinaRetrospective StudiesRisk FactorsSex FactorsSodium Potassium Chloride Symporter InhibitorsSulfonamidesTertiary Care CentersTorsemideTreatment OutcomeUltrasonographyConceptsHeart failure patientsFailure patientsEffects of torsemideFurosemide-treated patientsMore comorbiditiesCause mortalityBaseline characteristicsProspective trialHeart failureLoop diureticsResidual confoundingPatientsDuke HospitalFurosemideRisk adjustmentTorsemideMortalityLab databaseComorbiditiesDiureticsHospitalTrialsA reappraisal of loop diuretic choice in heart failure patients
Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, O'Connor CM. A reappraisal of loop diuretic choice in heart failure patients. American Heart Journal 2015, 169: 323-333. PMID: 25728721, PMCID: PMC4346710, DOI: 10.1016/j.ahj.2014.12.009.Peer-Reviewed Original ResearchConceptsHeart failure patientsHeart failureFailure patientsLoop diureticsNew York Heart Association functional classPlasma brain natriuretic peptide levelsYork Heart Association functional classBrain natriuretic peptide levelsHeart failure severityNatriuretic peptide levelsTranscardiac extractionAldosterone secretionAldosterone systemDiuretic useVentricular functionFurosemide useSymptom managementPharmacologic differencesCardiac fibrosisSurrogate markerMEDLINE searchPeptide levelsControl trialEconomic burdenFurosemide
2008
Evaluation of mechanical dyssynchrony and myocardial perfusion using phase analysis of gated SPECT imaging in patients with left ventricular dysfunction
Trimble MA, Borges-Neto S, Honeycutt EF, Shaw LK, Pagnanelli R, Chen J, Iskandrian AE, Garcia EV, Velazquez EJ. Evaluation of mechanical dyssynchrony and myocardial perfusion using phase analysis of gated SPECT imaging in patients with left ventricular dysfunction. Journal Of Nuclear Cardiology 2008, 15: 663-670. PMID: 18761269, PMCID: PMC3048059, DOI: 10.1016/j.nuclcard.2008.06.007.Peer-Reviewed Original ResearchConceptsLeft ventricular dysfunctionMechanical dyssynchronyQRS durationPhase SDHF patientsVentricular dysfunctionPerfusion abnormalitiesMyocardial perfusionGated SPECT myocardial perfusion imagingLV phase distributionPhase analysis indicesSPECT myocardial perfusion imagingHeart failure patientsCardiac resynchronization therapyMeasures of dyssynchronyMyocardial perfusion imagingSingle photon emissionLV dysfunctionFailure patientsResynchronization therapyEjection fractionElectrical dyssynchronyMyocardial functionDyssynchronyMyocardial thickening
2006
Use of Valsartan in Post-Myocardial Infarction and Heart Failure Patients
Liu PP, Maggioni A, Velazquez EJ. Use of Valsartan in Post-Myocardial Infarction and Heart Failure Patients. Journal Of The Renin-Angiotensin-Aldosterone System 2006, 7: s19-s22. PMID: 16986231, DOI: 10.3317/jraas.2006.019.Peer-Reviewed Original ResearchConceptsAng II receptor blockersHeart failureLV dysfunctionMyocardial infarctionStrong therapeutic rationaleUse of valsartanII receptor blockersLeft ventricular dysfunctionHeart failure patientsPost-MI patientsMain effector mechanismPost-myocardial infarctionLarge-scale trialsRAAS blockadeAldosterone systemReceptor blockersVentricular dysfunctionAssociated morbidityFailure patientsFrequent complicationSuch patientsACE inhibitorsSignificant morbiditySuch therapyDisease progressionAssociation of QRS duration and outcomes after myocardial infarction: the VALIANT trial
Yerra L, Anavekar N, Skali H, Zelenkofske S, Velazquez E, McMurray J, Pfeffer M, Solomon SD. Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. Heart Rhythm 2006, 3: 313-316. PMID: 16500304, DOI: 10.1016/j.hrthm.2005.11.024.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCohort StudiesElectrocardiographyFemaleFollow-Up StudiesHeart VentriclesHumansMaleMiddle AgedMyocardial InfarctionPrognosisStroke VolumeSurvival RateTetrazolesTreatment OutcomeValineValsartanVentricular Dysfunction, LeftConceptsQRS durationSudden deathCV deathAdverse outcomesMyocardial infarctionPost-myocardial infarction settingUnivariate relative riskLeft ventricular dysfunctionHeart failure patientsSymptoms of HFAcute myocardial infarctionDevelopment of HFEnd-systolic volumeLarger ventricular volumesQRS duration prolongationRecurrent MICardiovascular deathInitial electrocardiogramVentricular dysfunctionAcute MIFailure patientsSystolic functionEjection fractionIndependent predictorsClinical outcomes